Intervention of Shugan Xiaozhi Decoction on Nonalcoholic Fatty Liver Disease via Mediating Gut-Liver Axis

被引:5
|
作者
Yang, Huili [1 ,2 ]
Feng, Lian [1 ,2 ]
Xu, Linyi [1 ,2 ]
Jiang, Dansheng [1 ,2 ]
Zhai, Fenfen [3 ]
Tong, Guangdong [1 ]
Xing, Yufeng [1 ]
机构
[1] Shenzhen Tradit Chinese Med Hosp, Hepatol Dept, Shenzhen 518033, Guangdong, Peoples R China
[2] Guangzhou Univ Chinese Med, Clin Med Coll 4, Shenzhen 518033, Guangdong, Peoples R China
[3] Shenzhen Futian Ctr Chron Dis Control, Shenzhen 518048, Guangdong, Peoples R China
关键词
APOLIPOPROTEIN-B; PPAR-ALPHA; MICROBIOTA; METABOLISM; PROGRESSION; DEFICIENCY; DISORDERS; BACTERIA; RECEPTOR; OBESITY;
D O I
10.1155/2022/4801695
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disease with an increasing incidence rate but few therapies. Shugan Xiaozhi decoction (SX) has demonstrated beneficial effects in treating NAFLD with an unclear mechanism. This study was aimed at investigating the therapeutic mechanism of SX on high-fat diet-induced NAFLD rats via the gut-liver axis. Hepatic steatosis and integrity of intestinal mucosa in NAFLD rats were assessed by histopathological staining. The level of lipid and inflammation were estimated by enzyme-linked immunosorbent assay. Western Blotting was used to detect apolipoprotein (apo) B48 expression. 16S rRNA analysis was used to measure the changes of gut microbial composition after SX treatment. The expressions of zona occludens 1 protein (ZO-1), occludin, and secretory immunoglobulin A (sIgA) in the colon were detected by immunostaining to investigate the intestinal barrier function. Our study found that SX reduced hepatic steatosis, the levels of alanine aminotransferase, aspartate aminotransferase, total cholesterol, and triglyceride and apoB48 expression but increased peroxisome proliferator activated receptor alpha (PPAR alpha) level. Moreover, SX altered the diversity of gut microbiota, upregulating the relative abundance of f_Prevotellaceae, while downregulating f_Bacteroidales_ S24-7, f_Lachnospiraceae, f_Ruminococcaceae, f_Erysipelotrichaceae, and f_Desulfovibrionaceae. By increasing the expression of ZO-1 and occludin and decreasing the level of proinflammatory factors, including sIgA, lipopolysaccharide, tumor necrosis factor-alpha, interleukin-1 beta, monocyte chemotactic protein-1, and transforming growth factor-beta 1, SX improved intestinal mucosal integrity and barrier function. Our study illustrated that the gut-liver axis was a potential way for SX to ameliorate NAFLD, that is, by regulating the expression of PPAR alpha, apoB48, and modulating gut microbiota to protect the intestinal barrier function, and thus alleviate lipid deposition and inflammatory response in the liver.
引用
下载
收藏
页数:15
相关论文
共 50 条
  • [41] Gut-liver axis
    S. Zeuzem
    International Journal of Colorectal Disease, 2000, 15 : 59 - 82
  • [42] Gut-liver axis
    Zeuzem, S
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2000, 15 (02) : 59 - 82
  • [43] Importance of the gut microbiota in the gut-liver axis in normal and liver disease
    Kotlyarov, Stanislav
    WORLD JOURNAL OF HEPATOLOGY, 2024, 16 (06)
  • [44] Butyrate-Producing Probiotics Reduce Nonalcoholic Fatty Liver Disease Progression in Rats: New Insight into the Probiotics for the Gut-Liver Axis
    Endo, Hitoshi
    Niioka, Maki
    Kobayashi, Noriko
    Tanaka, Mamoru
    Watanabe, Tetsu
    PLOS ONE, 2013, 8 (05):
  • [45] Nonalcoholic Fatty Liver Disease (NAFLD) as Model of Gut-Liver Axis Interaction: From Pathophysiology to Potential Target of Treatment for Personalized Therapy
    Fianchi, Francesca
    Liguori, Antonio
    Gasbarrini, Antonio
    Grieco, Antonio
    Miele, Luca
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (12)
  • [46] The Gut-Liver Axis in Chronic Liver Disease: A Macrophage Perspective
    De Muynck, Kevin
    Vanderborght, Bart
    Van Vlierberghe, Hans
    Devisscher, Lindsey
    CELLS, 2021, 10 (11)
  • [47] Gut-liver axis in health and disease Abstracts
    不详
    CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2015, 1 (02) : 51 - 96
  • [48] Characterization of pattern recognition receptor expression for regulating myeloid cell responses in the gut-liver axis in nonalcoholic fatty liver disease and cholangiopathies
    Bruneau, Alix
    Wdowinski, Simon
    Hammerich, Linda
    Oezdirik, Burcin
    Sigal, Michael
    Demir, Muenevver
    Tacke, Frank
    JOURNAL OF HEPATOLOGY, 2023, 78 : S351 - S352
  • [49] Gut-liver axis in inflammatory bowel disease
    Egresi Anna
    Kovacs Agota
    Szilvas Agnes
    Blazovics Anna
    ORVOSI HETILAP, 2017, 158 (26) : 1014 - 1021
  • [50] Bifidobacterium-derived short-chain fatty acids and indole compounds attenuate nonalcoholic fatty liver disease by modulating gut-liver axis
    Yoon, Sang Jun
    Yu, Jeong Seok
    Min, Byeong Hyun
    Gupta, Haripriya
    Won, Sung-Min
    Park, Hee Jin
    Han, Sang Hak
    Kim, Byung-Yong
    Kim, Kyung Hwan
    Kim, Byoung Kook
    Joung, Hyun Chae
    Park, Tae-Sik
    Ham, Young Lim
    Lee, Do Yup
    Suk, Ki Tae
    FRONTIERS IN MICROBIOLOGY, 2023, 14